FDA-USPTO Collaboration: Stakeholders Want More Clarity On Orange Book Patent Listings

Officials from the two agencies note the real-world benefit of cross-training in helping patent examiners find prior art based on product labeling. A USPTO administrative patent judge also nixes a suggestion that the agency hold proceedings to determine if patents were properly listed in the Orange Book.  

FDA and USPTO
USPTO and FDA officials discussed the progress of their collaboration. • Source: Nielsen Hobbs; the Pink Sheet|Shutterstock images

More from US FDA

More from Agency Leadership